{
    "clinical_study": {
        "@rank": "45204", 
        "arm_group": [
            {
                "arm_group_label": "bimatoprost 0.01% and hypromellose 0.3%", 
                "arm_group_type": "Active Comparator", 
                "description": "Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks."
            }, 
            {
                "arm_group_label": "travatan 0.004% and timolol 0.5%", 
                "arm_group_type": "Active Comparator", 
                "description": "Travatan 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This efficacy and safety study will evaluate LUMIGAN\u00ae RC/ LUMIGAN\u00ae .01 (bimatoprost 0.01%)\n      alone compared to TRAVATAN Z\u00ae (travoprost 0.004%) and TIMOLOL MALEATE-EX, 0.5%/TIMOLOL GFS\n      0.5% (timolol 0.5% ophthalmic gel forming solution) in patients who require IOP lowering\n      therapy."
        }, 
        "brief_title": "An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ocular hypertension or glaucoma that requires treatment with medication\n\n          -  Have a best corrected visual acuity (BCVA) of  20/100 or better in both eyes\n\n        Exclusion Criteria:\n\n          -  History of LASIK, LASEK, RK, and/or PRK in the study eye(s)\n\n          -  History of any intraocular surgery or glaucoma laser surgery in the study eye(s)\n             within 3 months\n\n          -  Use of topical, periorbital, intravitreal or systemic steroid within 3 months or\n             expected use during the course of study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "94", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01881126", 
            "org_study_id": "GMA-LUM-12-021"
        }, 
        "intervention": [
            {
                "arm_group_label": "bimatoprost 0.01% and hypromellose 0.3%", 
                "description": "Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.", 
                "intervention_name": "bimatoprost 0.01%", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Lumigan\u00ae RC", 
                    "Lumigan\u00ae"
                ]
            }, 
            {
                "arm_group_label": "travatan 0.004% and timolol 0.5%", 
                "description": "Travatan 0.004% administered to both eyes once daily for 12 weeks.", 
                "intervention_name": "travatan 0.004%", 
                "intervention_type": "Drug", 
                "other_name": "Travatan Z\u00ae"
            }, 
            {
                "arm_group_label": "travatan 0.004% and timolol 0.5%", 
                "description": "Timolol 0.5% administered to both eyes once daily for 12 weeks.", 
                "intervention_name": "timolol 0.5%", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Timolol Maleate-EX", 
                    "Timolol GFS"
                ]
            }, 
            {
                "arm_group_label": "bimatoprost 0.01% and hypromellose 0.3%", 
                "description": "Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.", 
                "intervention_name": "hypromellose 0.3%", 
                "intervention_type": "Drug", 
                "other_name": "GenTeal\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Timolol", 
                "Travoprost", 
                "Bimatoprost", 
                "Cloprostenol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Barrie", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Intraocular Pressure (IOP) in the Study Eye", 
            "safety_issue": "No", 
            "time_frame": "Month 3"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01881126"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}